Molbio Diagnostics Reports Rs 52.7 Cr Profit in Q1, Reverses Previous Loss

Molbio Diagnostics, a recent entrant to the stock market, has reported a profit of Rs 52.74 crore for the first quarter ending June. This marks a significant turnaround from the Rs 23.94 crore loss recorded in the same period last year. The company's financial performance was buoyed by strong demand for its Truenat test kits.

IPO Boosts Financial Outlook

The company, which raised approximately Rs 940 crore through its Initial Public Offering (IPO) in August, saw its total income rise to Rs 411.48 crore in Q1 FY27, up from Rs 100.47 crore in the corresponding quarter of the previous fiscal year. The IPO, completed on August 17, has evidently provided a substantial boost to the company's financial resources.

Surge in Truenat Test-Kit Sales

A key driver of Molbio Diagnostics' improved financial results was the increased volume of Truenat test-kit sales. The company reported sales of 62.4 lakh units in the first quarter, a dramatic increase from the 7.9 lakh units sold in the same period last year. Truenat test kits are designed to detect a broad range of infectious diseases quickly and accurately at the point of care, contributing to their rising demand.

Leadership Comments

Sriram Natarajan, Executive Director and CEO of Molbio Diagnostics, highlighted the significance of the company's transition to a listed entity and its positive start to the fiscal year. "FY27 is a milestone year for Molbio, marking our transition to a listed company. We have begun the year on a strong note, with healthy growth across both revenue and profitability in Q1," Natarajan stated.

The strong financial results underscore the company's strategic focus on expanding its diagnostic offerings and leveraging its IPO proceeds to enhance operational capabilities.